Answers are grounded in this paper and cite their sources.
A 28-year-old woman with recently diagnosed chronic myelogenous leukemia (CML) presents for consideration of appropriate treatment. No siblings are available as candidate donors for stem-cell transplantation. Imatinib, an inhibitor of the BCR-ABL tyrosine kinase present in almost all CML, is recommended. The patient may need to take imatinib indefinitely to maintain suppression of abnormal bone marrow clones.
No takes yet. Share an insight, caveat, or question.
Charles A. Schiffer (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: